Advanced

Biomarkers for tau pathology

Schöll, Michael LU ; Maass, Anne; Mattsson, Niklas LU ; Ashton, Nicholas J.; Blennow, Kaj LU ; Zetterberg, Henrik LU and Jagust, William (2019) In Molecular and Cellular Neuroscience 97. p.18-33
Abstract

The aggregation of fibrils of hyperphosphorylated and C-terminally truncated microtubule-associated tau protein characterizes 80% of all dementia disorders, the most common neurodegenerative disorders. These so-called tauopathies are hitherto not curable and their diagnosis, especially at early disease stages, has traditionally proven difficult. A keystone in the diagnosis of tauopathies was the development of methods to assess levels of tau protein in vivo in cerebrospinal fluid, which has significantly improved our knowledge about these conditions. Tau proteins have also been measured in blood, but the importance of tau-related changes in blood is still unclear. The recent addition of positron emission tomography ligands to visualize,... (More)

The aggregation of fibrils of hyperphosphorylated and C-terminally truncated microtubule-associated tau protein characterizes 80% of all dementia disorders, the most common neurodegenerative disorders. These so-called tauopathies are hitherto not curable and their diagnosis, especially at early disease stages, has traditionally proven difficult. A keystone in the diagnosis of tauopathies was the development of methods to assess levels of tau protein in vivo in cerebrospinal fluid, which has significantly improved our knowledge about these conditions. Tau proteins have also been measured in blood, but the importance of tau-related changes in blood is still unclear. The recent addition of positron emission tomography ligands to visualize, map and quantify tau pathology has further contributed with information about the temporal and spatial characteristics of tau accumulation in the living brain. Together, the measurement of tau with fluid biomarkers and positron emission tomography constitutes the basis for a highly active field of research. This review describes the current state of biomarkers for tau biomarkers derived from neuroimaging and from the analysis of bodily fluids and their roles in the detection, diagnosis and prognosis of tau-associated neurodegenerative disorders, as well as their associations with neuropathological findings, and aims to provide a perspective on how these biomarkers might be employed prospectively in research and clinical settings.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Molecular and Cellular Neuroscience
volume
97
pages
18 - 33
publisher
Elsevier
external identifiers
  • scopus:85058245414
ISSN
1044-7431
DOI
10.1016/j.mcn.2018.12.001
language
English
LU publication?
yes
id
914c0c79-ff62-4545-b7d1-14bd464bf1eb
date added to LUP
2019-01-10 09:45:37
date last changed
2019-10-15 06:53:49
@article{914c0c79-ff62-4545-b7d1-14bd464bf1eb,
  abstract     = {<p>The aggregation of fibrils of hyperphosphorylated and C-terminally truncated microtubule-associated tau protein characterizes 80% of all dementia disorders, the most common neurodegenerative disorders. These so-called tauopathies are hitherto not curable and their diagnosis, especially at early disease stages, has traditionally proven difficult. A keystone in the diagnosis of tauopathies was the development of methods to assess levels of tau protein in vivo in cerebrospinal fluid, which has significantly improved our knowledge about these conditions. Tau proteins have also been measured in blood, but the importance of tau-related changes in blood is still unclear. The recent addition of positron emission tomography ligands to visualize, map and quantify tau pathology has further contributed with information about the temporal and spatial characteristics of tau accumulation in the living brain. Together, the measurement of tau with fluid biomarkers and positron emission tomography constitutes the basis for a highly active field of research. This review describes the current state of biomarkers for tau biomarkers derived from neuroimaging and from the analysis of bodily fluids and their roles in the detection, diagnosis and prognosis of tau-associated neurodegenerative disorders, as well as their associations with neuropathological findings, and aims to provide a perspective on how these biomarkers might be employed prospectively in research and clinical settings.</p>},
  author       = {Schöll, Michael and Maass, Anne and Mattsson, Niklas and Ashton, Nicholas J. and Blennow, Kaj and Zetterberg, Henrik and Jagust, William},
  issn         = {1044-7431},
  language     = {eng},
  pages        = {18--33},
  publisher    = {Elsevier},
  series       = {Molecular and Cellular Neuroscience},
  title        = {Biomarkers for tau pathology},
  url          = {http://dx.doi.org/10.1016/j.mcn.2018.12.001},
  volume       = {97},
  year         = {2019},
}